Rituximab in Idiopathic Pulmonary Hemosiderosis in Children: A Novel and Less Toxic Treatment Option

Idiopathic pulmonary hemosiderosis (IPH) is a rare, potentially life-threatening chronic disease. Steroids are the cornerstone of treatment, even though toxicity and side-effects are very common. Recently, rituximab (RTX) has been suggested as a treatment option, although evidence for its efficacy a...

Descripción completa

Detalles Bibliográficos
Autores principales: Terheggen-Lagro, Suzanne W. J., Haarman, Eric G., Rutjes, Niels W., van den Berg, J. Merlijn, Schonenberg-Meinema, Dieneke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784529/
https://www.ncbi.nlm.nih.gov/pubmed/36559000
http://dx.doi.org/10.3390/ph15121549

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784529/
https://www.ncbi.nlm.nih.gov/pubmed/36559000
http://dx.doi.org/10.3390/ph15121549

Ejemplares similares